(Reuters) - Lipitor is the world's top-selling drug and amounted to more than one-fourth of Pfizer's $48 billion in revenue last year. The company has been defending its intellectual property for the drug around the world against generic drugmaker Ranbaxy.
Pfizer, the world's largest drugmaker, also is trying to protect Lipitor's market share against an influx of inexpensive generic versions of other cholesterol medicines.
Read more at Reuters.com Business News
Pfizer, the world's largest drugmaker, also is trying to protect Lipitor's market share against an influx of inexpensive generic versions of other cholesterol medicines.
Read more at Reuters.com Business News
No comments:
Post a Comment